CliffBio
small molecule

DOVATO

DOLUTEGRAVIR SODIUM; LAMIVUDINE

Loss of exclusivityJanuary 2031latest FDA-listed patent expiry
CompanyViiV Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameDOVATO
Active ingredientDOLUTEGRAVIR SODIUM; LAMIVUDINE
StrengthEQ 50MG BASE;300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2019
Marketing statusRX

Listed patents

PatentExpiresType
11234985January 2031product
9242986*PEDJune 2030—
9242986December 2029substance, product
8129385*PEDApril 2028—
8129385October 2027substance, product

Regulatory exclusivity

CodeExpires
NPPApril 2027

More from ViiV Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.